HUP0300615A2 - Sibutramint és orlistatot tartalmazó gyógyszerkészítmény - Google Patents

Sibutramint és orlistatot tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0300615A2
HUP0300615A2 HU0300615A HUP0300615A HUP0300615A2 HU P0300615 A2 HUP0300615 A2 HU P0300615A2 HU 0300615 A HU0300615 A HU 0300615A HU P0300615 A HUP0300615 A HU P0300615A HU P0300615 A2 HUP0300615 A2 HU P0300615A2
Authority
HU
Hungary
Prior art keywords
compound
formula
therapeutic agents
treatment
effective amount
Prior art date
Application number
HU0300615A
Other languages
English (en)
Inventor
David John Heal
Helen Christine Jackson
Original Assignee
Abbott Gmbh & Co. Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg. filed Critical Abbott Gmbh & Co. Kg.
Publication of HUP0300615A2 publication Critical patent/HUP0300615A2/hu
Publication of HUP0300615A3 publication Critical patent/HUP0300615A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány tárgya eljárás kövérség (elhízás) kezelésére egy ilyenkezelést igénylő emberben, az embernek beadva egy általános képletűvegyület, ennek enantiomerei és gyógyszerészetileg elfogadható sói - aképletben R1 és R2 egymástól függetlenül hidrogénatom vagymetilcsoport - terápiásan hatásos mennyiségét, és a képletű vegyületterápiásan hatásos mennyiségét, az (I) általános képletű vegyületet ésa (II) képletű vegyületet egyidejűleg, külön vagy egymás utánalkalmazva. Ó
HU0300615A 1997-12-24 1998-12-16 Therapeutic agents HUP0300615A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9727131.6A GB9727131D0 (en) 1997-12-24 1997-12-24 Therapeutic agents
PCT/EP1998/008249 WO1999033450A2 (en) 1997-12-24 1998-12-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (2)

Publication Number Publication Date
HUP0300615A2 true HUP0300615A2 (hu) 2003-07-28
HUP0300615A3 HUP0300615A3 (en) 2005-04-28

Family

ID=10824083

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300615A HUP0300615A3 (en) 1997-12-24 1998-12-16 Therapeutic agents

Country Status (26)

Country Link
US (1) US6403641B2 (hu)
EP (1) EP1039900B1 (hu)
JP (1) JP2001527036A (hu)
KR (1) KR20010033531A (hu)
CN (1) CN1134257C (hu)
AT (1) ATE268174T1 (hu)
AU (1) AU758181B2 (hu)
BG (1) BG104568A (hu)
BR (1) BR9814498A (hu)
CA (1) CA2315259A1 (hu)
CZ (1) CZ20002392A3 (hu)
DE (1) DE69824313T2 (hu)
DK (1) DK1039900T3 (hu)
ES (1) ES2222001T3 (hu)
GB (1) GB9727131D0 (hu)
HK (1) HK1034446A1 (hu)
HU (1) HUP0300615A3 (hu)
IL (1) IL136733A (hu)
NO (1) NO20003313L (hu)
NZ (1) NZ505686A (hu)
PL (1) PL342099A1 (hu)
PT (1) PT1039900E (hu)
SK (1) SK9492000A3 (hu)
TR (1) TR200001869T2 (hu)
UA (1) UA70310C2 (hu)
WO (1) WO1999033450A2 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
EP1307264B1 (en) 2000-07-28 2004-10-20 F. Hoffmann-La Roche Ag New pharmaceutical composition
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
CA2530634A1 (en) * 2003-06-12 2004-12-23 Menachem Rubinstein Methods of treating obesity and related disorders using tellurium and selenium compounds
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
US8877267B2 (en) 2004-05-10 2014-11-04 University Of Copenhagen Flaxseeds for body weight management
EP2190303A1 (en) 2007-09-12 2010-06-02 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
JP5738011B2 (ja) * 2011-03-04 2015-06-17 株式会社ブリヂストン 二次電池の非水電解液用添加剤、二次電池用非水電解液及び非水電解液二次電池
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
TR200001869T2 (tr) 2000-10-23
IL136733A (en) 2004-08-31
DE69824313T2 (de) 2005-08-25
US6403641B2 (en) 2002-06-11
US20020010160A1 (en) 2002-01-24
AU2273899A (en) 1999-07-19
CN1134257C (zh) 2004-01-14
NO20003313D0 (no) 2000-06-23
DK1039900T3 (da) 2004-10-04
ES2222001T3 (es) 2005-01-16
JP2001527036A (ja) 2001-12-25
SK9492000A3 (en) 2001-07-10
KR20010033531A (ko) 2001-04-25
PL342099A1 (en) 2001-05-21
WO1999033450A3 (en) 1999-09-02
NZ505686A (en) 2002-07-26
IL136733A0 (en) 2001-06-14
HK1034446A1 (en) 2001-10-26
DE69824313D1 (de) 2004-07-08
UA70310C2 (uk) 2004-10-15
CN1284872A (zh) 2001-02-21
PT1039900E (pt) 2004-09-30
CZ20002392A3 (cs) 2002-01-16
GB9727131D0 (en) 1998-02-25
EP1039900A2 (en) 2000-10-04
BG104568A (bg) 2001-02-28
HUP0300615A3 (en) 2005-04-28
ATE268174T1 (de) 2004-06-15
AU758181B2 (en) 2003-03-20
WO1999033450A2 (en) 1999-07-08
BR9814498A (pt) 2000-10-10
NO20003313L (no) 2000-08-11
CA2315259A1 (en) 1999-07-08
EP1039900B1 (en) 2004-06-02

Similar Documents

Publication Publication Date Title
HUP0300615A2 (hu) Sibutramint és orlistatot tartalmazó gyógyszerkészítmény
HUP0200469A2 (hu) Szulfamátszármazékok alkalmazása az impulzus kontrol zavarok kezelésére
PT1333887E (pt) Metodo de tratamento de desordens musculares
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE122010000050I2 (de) Sublinguales oder bukkales arzneimittel.
HUP0002347A2 (hu) Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MX9707453A (es) Derivados de quinazolina.
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
NO952309L (no) Anvendelse av riluzol ved behandling av Parkinsons sykdom og Parkinsonske syndromer
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
DK0583271T3 (da) Arylmorpholin, fremstilling og anvendelse
SE9902597D0 (sv) New use
HUP0201878A2 (hu) Sibutramint és orlistatot tartalmazó gyógyszerkészítmények
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
SE9603285D0 (sv) New compounds
HUP0201880A2 (hu) Szibutramint és lipáz inhibitort tartalmazó gyógyszerkészítmények
MY134074A (en) Pharmaceutical composition comprising gamma-butyrobetaine for treatment of impotence
SE9603284D0 (sv) New compounds
DK0967986T3 (da) Anvendelse af humant alfa1-surt glycoprotein til fremstilling af et farmaceutisk præparat
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees